THERAPY DOSSIER · th-c6f3f28d8148

CpG oligodeoxynucleotide (CpG ODN)

Other · CpG oligodeoxynucleotide, a TLR9-agonist immunostimulatory oligonucleotide.

Evidence & regulatory context

Mechanism: CpG oligodeoxynucleotide, a TLR9-agonist immunostimulatory oligonucleotide.
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00824733 ↗PHASE2terminated

Subcutaneous CpG ODN (PF-3512676) + Trastuzumab in Metastatic Breast Cancer

Breast Cancer

Enrolment: 6 · Results not recorded

NCT00562939 ↗PHASE1/PHASE2completed

TLR9-Agonist (CPG 7909) Adjuvanted Pneumococcal Vaccination in HIV-Infected Adults

HIV Infections

Enrolment: 97 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30953359 ↗2019Mixed findings

A study on the protective effects of CpG oligodeoxynucleotide-induced mucosal immunity against lung injury in a mouse acute respiratory distress syndrome model.

MouseEndotoxin/LPSBALB/cIntranasal and transrectal50 microgram intranasally; 20 microgram transrectallyImmunisation before, or on days 3 and 7 after, establishing the ARDS model

Model: Lipopolysaccharide-induced acute respiratory distress syndrome

CpG ODN given after model induction improved lung pathology, with intranasal 50 microgram producing the least severe injury and the lowest IL-6 and IL-8 levels, followed by rectal 20 microgram. Nasal or rectal CpG ODN given before LPS showed no significant protective effect.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…